Search alternatives:
clinical decrease » clinical disease (Expand Search), clinical case (Expand Search), linear decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
i.e decrease » we decrease (Expand Search), sizes decrease (Expand Search), use decreased (Expand Search)
Showing 1 - 20 results of 4,682 for search '(( significant clinical decrease ) OR ( significant ((i.e decrease) OR (teer decrease)) ))', query time: 0.68s Refine Results
  1. 1
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  3. 3
    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  4. 4
    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  5. 5
    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx

    Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  6. 6
    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  7. 7
    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  8. 8
    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg

    Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  9. 9
    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx

    Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

    Published 2025
    “…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”
    Save to List
    Saved in:
  10. 10
    Intervention with MLKL decreased neutrophil death and protected mice against <i>E. coli</i> pneumonia.

    Intervention with MLKL decreased neutrophil death and protected mice against <i>E. coli</i> pneumonia. by Qinyu Luo (13000956)

    Published 2025
    Save to List
    Saved in:
  11. 11
    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells.

    BA attenuated the decrease in the expression of ZO-1 and Occludin induced by LPS in Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  12. 12
    BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers.

    BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  13. 13
    <i>e-lgp</i> curve of improved red clay.

    <i>e-lgp</i> curve of improved red clay. by Quan Shen (37564)

    Published 2025
    Save to List
    Saved in:
  14. 14
    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.

    Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers. by Luqiong Liu (11537092)

    Published 2024
    “…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. (<b>B)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on day 22. …”
    Save to List
    Saved in:
  15. 15
    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells.

    Y-27632 synergized with BA to alleviate the decrease in the expression of and abnormal localization of ZO-1 and Occludin in LPS-induced Caco2 cells. by Luqiong Liu (11537092)

    Published 2024
    Save to List
    Saved in:
  16. 16
    The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER.

    The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. by Charlotte J. van Ginkel (20790466)

    Published 2025
    “…PS decreased TEER. (C) Different treatments (treatment groups n = 8)with HA and/or CS did not affect TEER recovery after PS treatment, full recovery was seen in all groups after 24 hours. …”
    Save to List
    Saved in:
  17. 17
    Graphical presentation of % decrease for insulin from baseline at different conditions.

    Graphical presentation of % decrease for insulin from baseline at different conditions. by Nathan Mubiru (21627195)

    Published 2025
    Save to List
    Saved in:
  18. 18
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Save to List
    Saved in:
  19. 19
    Clinical course of patient no.

    Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    Graphical presentation of % decrease for C-peptide from baseline at different conditions.

    Graphical presentation of % decrease for C-peptide from baseline at different conditions. by Nathan Mubiru (21627195)

    Published 2025
    Save to List
    Saved in:

Search Tools: